Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy

被引:33
作者
Atwell, Graham J. [1 ]
Yang, Shangjin [1 ]
Pruijn, Frederik B. [1 ]
Pullen, Susan M. [1 ]
Hogg, Alison [1 ]
Patterson, Adam V. [1 ]
Wilson, William R. [1 ]
Denny, William A. [1 ]
机构
[1] Univ Auckland, Sch Med Sci, Auckland Canc Soc Res Ctr, Auckland 1142, New Zealand
关键词
BIOREDUCTIVE DRUG; CB; 1954; ENZYME; CYTOTOXICITY; CB-1954; BIOACTIVATION; EXPRESSION; ACTIVATION; MUSTARDS; SN-23862;
D O I
10.1021/jm061062o
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 2,4-dinitrobenzamide mustards were prepared from 5-chloro-2,4-dinitrobenzoic acid or the corresponding 5-dimesylate mustard as potential prodrugs for gene-directed enzyme prodrug therapy (GDEPT) with the E. coli nfsB nitroreductase (NTR). The compounds, including 32 new examples, were evaluated in four pairs of NTR+ve/-ve cell lines for selective cytotoxicity (IC50 and IC50 ratios), in multicellular layer (MCL) cultures for bystander effects, and for in vivo activity against tumors grown from stably NTR transfected EMT6 and WiDr cells in nude mice. Multivariate regression analysis of the IC50 results was undertaken using a partial least-squares projection to latent structures model. In NTR-ve lines, cytotoxicity correlated positively with logP, negatively with hydrogen bond acceptors (HA) and donors (HD) in the amide side chain, and positively with the reactivity of the less-reactive leaving group of the mustard function, likely reflecting toxicity due to DNA monoadducts. Potency and selectivity for NTR+ve lines was increased by logP and HD, decreased by HA, and was positively correlated with the leaving group efficiency of the more-reactive group, likely reflecting DNA crosslinking. NTR selectivity was greatest for asymmetric chloro/mesylate and bromo/mesylate mustards. Bystander effects in the MCL assay also correlated positively with logP and negatively with leaving group reactivity, presumably reflecting the transcellular diffusion/reaction properties of the activated metabolites. A total of 18 of 22 mustards showed equal or greater bystander efficiencies in MCLs than the aziridinylbenzamide CB 1954, which is currently in clinical trial for NTR-GDEPT. The dibromo and bromomesylate mustards were surprisingly well tolerated in mice. High MTD/IC50 (NTR+ve) ratios translated into curative activity of several compounds against NTR+ve tumors. A bromomesylate mustard showed superior activity against WiDr tumors grown from 1:9 mixtures of NTR+ve and NTR-ve cells, indicating a strong bystander effect in vivo.
引用
收藏
页码:1197 / 1212
页数:16
相关论文
共 29 条
[1]   THE BIOACTIVATION OF 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) .1. PURIFICATION AND PROPERTIES OF A NITROREDUCTASE ENZYME FROM ESCHERICHIA-COLI - A POTENTIAL ENZYME FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) [J].
ANLEZARK, GM ;
MELTON, RG ;
SHERWOOD, RF ;
COLES, B ;
FRIEDLOS, F ;
KNOX, RJ .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (12) :2289-2295
[2]   BIOACTIVATION OF DINITROBENZAMIDE MUSTARDS BY AN ESCHERICHIA-COLI-B NITROREDUCTASE [J].
ANLEZARK, GM ;
MELTON, RG ;
SHERWOOD, RF ;
WILSON, WR ;
DENNY, WA ;
PALMER, BD ;
KNOX, RJ ;
FRIEDLOS, F ;
WILLIAMS, A .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (05) :609-618
[3]  
Atwell GJ, 1996, ANTI-CANCER DRUG DES, V11, P553
[4]   Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954 [J].
Bridgewater, JA ;
Springer, CJ ;
Knox, RJ ;
Minton, NP ;
Michael, NP ;
Collins, MK .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) :2362-2370
[5]   The bystander effect of the nitroreductase CB 1954 enzyme prodrug system is due to a cell-permeable metabolite [J].
Bridgewater, JA ;
Knox, RJ ;
Pitts, JD ;
Collins, MK ;
Springer, CJ .
HUMAN GENE THERAPY, 1997, 8 (06) :709-717
[6]  
Chung-Faye G, 2001, CLIN CANCER RES, V7, P2662
[7]   CONSIDERATIONS FOR THE DESIGN OF NITROPHENYL MUSTARDS AS AGENTS WITH SELECTIVE TOXICITY FOR HYPOXIC TUMOR-CELLS [J].
DENNY, WA ;
WILSON, WR .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (06) :879-887
[8]   Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954 [J].
Djeha, AH ;
Hulme, A ;
Dexter, MT ;
Mountain, A ;
Young, LS ;
Searle, PF ;
Kerr, DJ ;
Wrighton, CJ .
CANCER GENE THERAPY, 2000, 7 (05) :721-731
[9]   Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy [J].
Friedlos, F ;
Denny, WA ;
Palmer, BD ;
Springer, CJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (08) :1270-1275
[10]   Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase [J].
Friedlos, F ;
Court, S ;
Ford, M ;
Denny, WA ;
Springer, C .
GENE THERAPY, 1998, 5 (01) :105-112